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Objectives: Fibromyalgia (FM) is a complex syndrome that is characterized by lasting and
diffuse chronic musculoskeletal pain, derived from non-inﬂammatory causes and classically
associated with the presence of speciﬁc tender points. However, studies have highlighted
other important symptoms associated with a lower quality of life (QOL) in FM,  such as
sleep  disturbances and alexithymia. This study aimed to investigate the pain, sleep and
alexithymia patterns of FM patients treated in a Brazilian tertiary center.
Methods: 20 patients with FM who were followed-up in the Rheumatology outpatient clinic
of  a Brazilian tertiary center (Faculdade de Medicina de São José do Rio Preto – FAMERP,
São Paulo, Brazil) and 20 patients without FM from other outpatient services of the FAMERP
completed a clinical and socio-demographic questionnaire, the Fibromyalgia Impact Ques-
tionnaire (FIQ), the Pittsburgh Sleep Quality Index (PSQI), the Toronto Alexithymia Scale
(TAS-20) and the SF-36 (WHOQOL).
Results: The patients with FM presented worse performances in all QOL dimensions of the
SF-36  and higher scores on the PSQI (p = 0.01), and the TAS-20 (p = 0.02). Patients with FM
also scored signiﬁcantly higher in all speciﬁc domains of PSQI and TAS-20.
Discussion: The present data were in accordance with literature, disclosing a worse per-
formance of patients with FM on pain impact, sleep complains and more presence of
alexithymia.
Conclusion: Studies have disclosed the presence of important and frequently underdiag-
nosed symptoms beyond pain complaints in FM, such as sleep complaints and alexithymia,
and a better knowledge of such disturbances might improve FM patients’ approach andtreatment.
©  2014 Elsevier Editora Ltda. All rights reserved.
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Caracterizac¸ão dos  padrões  de  dor,  sono  e  alexitimia  em  pacientes  com
ﬁbromialgia  atendidos  em  um  centro  terciário  brasileiro
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Objetivos: Fibromialgia (FM) é uma síndrome complexa, caracterizada por uma dor mus-
culoesquelética crônica duradoura e difusa, derivada de causas não inﬂamatórias e
classicamente associada à presenc¸a de pontos sensíveis especíﬁcos. No entanto, estudos
destacaram outros sintomas importantes associados à má qualidade de vida (QDV) em
pacientes com FM, por exemplo, distúrbios do sono e alexitimia. Esse estudo teve por obje-
tivo  investigar os padrões de dor, sono e alexitimia de pacientes com FM em um centro
terciário brasileiro.
Métodos: 20 pacientes com FM acompanhados na clínica ambulatorial de reumatologia de
um centro terciário brasileiro (Faculdade de Medicina de São José do Rio Preto – FAMERP,
São  Paulo, Brasil) e 20 pacientes sem FM provenientes de outros servic¸os ambulatoriais da
FAMERP completaram um questionário clínico e sociodemográﬁco, o Fibromyalgia Impact
Questionnaire (FIQ), o Pittsburgh Sleep Quality Index (PSQI), o Toronto Alexithymia Scale (TAS-20)
e  o SF-36 (WHOQOL).
Resultados: Os pacientes com FM tiveram desempenhos piores em todas as dimensões de
QDV  do SF-36 e escores mais altos no PSQI (P = 0,01) e no TAS-20 (P = 0,02). Pacientes com FM
também tiveram escores signiﬁcativamente mais altos em todos os domínios especíﬁcos do
PSQI e TAS-20.
Discussão: Os presentes dados concordavam com a literatura, evidenciando pior desem-
penho de pacientes com FM no impacto da dor, queixas de sono e maior presenc¸a de
alexitimia.
Conclusão: Estudos evidenciaram, além das queixas de dor, a presenc¸a de sintomas impor-
tantes e frequentemente subdiagnosticados, em pacientes com FM, como queixas relativas
ao  sono e alexitimia. Um conhecimento mais aprofundado desses distúrbios poderia mel-
horar  a abordagem e o tratamento dos pacientes com FM.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.
patient group were an age between 18 and 65 years, the pres-Introduction
Fibromyalgia (FM) is a complex syndrome that is charac-
terized by lasting and diffuse chronic musculoskeletal pain,
derived from non-inﬂammatory causes and classically asso-
ciated with the presence of speciﬁc tender points.1–5 It is the
second most common rheumatologic disease, with a world-
wide prevalence of 0.5% to 5%. Women aged between 40 and 55
years are predominantly affected, with a prevalence approx-
imately seven fold higher than in men.1,4,5 The diagnosis of
FM remains essentially clinical, although the aid of subsidiary
exams can be useful for associated diagnosis.5–7
Recent studies have highlighted other important symp-
toms associated with a lower quality of life (QOL) in FM,  such as
sleep disturbances and alexithymia.8–10 The major sleep com-
plaints reported by patients include insomnia, feeling tired
upon waking, decreased sleep time and an increased number
of sleep interruptions per night. In addition, the high preva-
lence of sleep disorders in patients with FM impairs their
QOL in two ways: difﬁculty obtaining restorative sleep and
increased sleepiness during the day, characterized by difﬁculty
maintaining wakefulness.8–10
In accordance with the deﬁnition provided by Campbell
(1996), “alexithymia” is characterized by difﬁculty identifying
one’s own emotional state, with the inability to focus on exter-
nal and somatic interests and to productively fantasize.11–15Studies have reported that FM patients have a speciﬁc difﬁ-
culty in recognizing their own emotions in association with
more complaints of increased pain, fatigue and decreased
physical function.14–16 In addition to alexithymia, patients
exhibit “sensory ampliﬁcation”, which consists of a greater
sensitivity and responsiveness to different sensory stimuli,
including pain.17 Based on these deﬁnitions and previous
studies of FM, the present study aimed to investigate, in a more
detailed manner, the pain, sleep and alexithymia patterns of
FM patients treated in a Brazilian tertiary center.
Patients  and  methods
Participants
The included patients were followed-up in the Rheumatology
outpatient clinic of a Brazilian tertiary center (Faculdade de
Medicina de São José do Rio Preto – FAMERP, São José do Rio
Preto, Brazil), and all patients were receiving treatment at the
time of the study. After receiving Ethical Committee approval,
the advantages and risks of participation were explained, and
informed consent was obtained. The inclusion criteria for theence of a current diagnosis of FM accordingly to the American
College of Rheumatology (ACR) and having been treated in our
unit for at least six months. Patients younger than 18 years or
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Table 1 – Demographic data of patients with ﬁbromyalgia and a control group.
Demographic data FM CG P
Number of subjects 20 20 -
Age in years (mean ± SD) 32.7 ± 9.1 32.2 ± 7.1 0.82
Number of females (%) 19 (95) 18 (90) 0.85
o
a
F
d
–
F
i
b
P
A
a
t
a
d
S
D
dYears of schooling (mean ± SD) 9.2 ± 6.3 
CG, control group; FM, ﬁbromyalgia group; SD, standard deviation.
lder than 65 years, those with pain syndromes not diagnosed
s FM and with any other rheumatologic disease in addition to
M were excluded. The study sample included 40 individuals
ivided into two groups: 20 patients with FM (patient group
 PG) and 20 patients from other outpatient services of the
AMERP (control group – CG). These groups were created to
nclude patients exposed to similar levels of hospital stress in
oth groups, eliminating this possible bias.
rocedures
 clinical and socio-demographic questionnaire including
ge, gender, schooling, psychiatric family history and drug
reatment was administered. The FM patients were then
dministered speciﬁc questionnaires:
a) Fibromyalgia Impact Questionnaire (FIQ) – to analyze speciﬁc
aspects of the pain complaints. This instrument has ten
domains (functional capacity, well-being, work absences,
ability to work, pain, fatigue, sleep, morning stiffness, anx-
iety and depression), and the general score can range from
0 to 80. Patients with higher pain impact present higher
scores;
b) Pittsburgh Sleep Quality Index (PSQI) – to analyze aspects
associated with sleep. This instrument has seven domains
(subjective sleep quality, sleep latency, sleep duration,
habitual sleep efﬁciency, sleep disorders, use of medica-
tions for sleep and daytime dysfunction). The maximum
total score is 21 points, and the higher the value, the lower
the quality of sleep evidenced. Total scores greater than 5
are indicative of poor sleep quality;
c) Toronto Alexithymia Scale (TAS-20) – to assess the presence of
symptoms associated with alexithymia. This instrument
examines three main domains: ability to identify and to
describe feelings, and to distinguish feelings of bodily sen-
sations, ability to daydream and preference for focusing on
external events rather than inner experiences. The score
indicated by the instrument ranges from 26 to 130. Values
lower than 62 do not indicate symptoms of alexithymia,
and values higher than 74 indicate the presence of these
symptoms. Values between 63 and 73 are inconclusive;
) The SF-36 (WHOQOL) – to analyze the QOL in eight
domains: functional, limitations due to physical aspects,
bodily pain, general health, vitality, social functioning,
emotional health and mental health. The lower the score
is, the worse the QOL.tatistics
emographic data are presented as the mean ± standard
eviation. Age and gender matching between patients and12.8 ± 5.1 0.12
controls were evaluated using the two independent samples
t-test and Fisher’s exact test, respectively. Data from the ques-
tionnaires were analyzed using nonparametric tests (unpaired
t-test, Mann-Whitney Test and Spearman correlation). The
statistical signiﬁcance level was set at 5%.
Results
Thirty-seven females (19 from the PG and 18 from the CG)
and three males (one from the PG and two from the CG)
were enrolled in the study. Groups were matched by gen-
der (p = 0.85), age (p = 0.82) and years of schooling (p = 0.12)
(Table 1).
Regarding the impact of FM as assessed by the FIQ, there
were signiﬁcant differences between the PG and the CG. The
mean general score was 52.0 ± 13.54 for the PG and 26.0 ± 16.06
for the CG (p < 0.0001). Higher scores were observed in the PG in
all 10 domains. The SF-36 also showed signiﬁcant differences
between both groups, with the PG presenting signiﬁcantly
lower mean scores in all eight domains compared with the
CG. Regarding the sleep aspects assessed by the PSQI, there
was a signiﬁcant difference between the total scores of the
CG (6.65 ± 4.46) and the PG (11.65 ± 4.48) (p = 0.01). The PG
scored higher in all seven domains of the PSQI. Regarding the
symptoms of alexithymia assessed by the TAS-20, the mean
total score was 67.10 ± 9.34 for the PG and 59.15 ± 8.70 for the
CG (p = 0.03). Comparisons between the two  groups for the
domains of all of the instruments are shown in Table 2.
Discussion
FM is a complex disease with a signiﬁcant prevalence among
the general population and is characterized by complaints
of pain that are often underdiagnosed. Moreover, the cur-
rent literature highlights the existence of other important
and underdiagnosed symptoms, such as sleep disturbances
and alexithymia, which could be associated with lower QOL
among patients with FM. Thus, the investigation of these
aspects and the search for tools to assess such complaints are
necessary.6–18
In the present study, the FIQ differentiated the impact of
pain between the PG and the CG, disclosing a higher impact
in the PG compared to the CG in all 10 ﬁelds, as originally
expected. Other studies have conﬁrmed this ﬁnding, reporting
impairments of the same skills in patients with FM.6–10,18,19 In
addition, the results regarding the QOL measured using the
SF-36 showed an overall reduction in all domains of the ques-
tionnaire in the PG compared with the CG. This observation
has also been described in other studies showing the negative
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Table 2 – Comparisons of the domains of all tested instruments between the patient and control groups.
Instrument Domain PG
(mean ± SD)
CG
(mean ± SD)
p
Fibromyalgia Impact
Questionnaire (FIQ)
Functional capacity 3.0 ± 2.59 1.0 ± 0.39 0.001a
Well-being 6.0 ± 3.52 4.0 ± 3.85 0.09
Work absences 3.0 ± 2.12 1.0 ± 0.84 0.004a
Ability to work 6.0 ± 2.95 1.0 ± 1.50 <0.001a
Fatigue 7.0 ± 2.85 2.0 ± 1.49 <0.001a
Sleep 8.0 ± 2.62 5.0 ± 3.56 0.004a
Morning stiffness 7.0 ± 3.07 1.0 ± 0.86 <0.001a
Anxiety 7.0 ± 3.23 5.0 ± 3.07 0.04a
Depression 7.0 ± 3.57 4.0 ± 3.15 0.007a
SF-36 (WHOQOL) Functional skills 41.75 ± 25.89 80.0 ± 28.35 <0.001a
Physical aspects 17.50 ± 28.67 76.0 ± 30.87 <0.001a
Bodily pain 32.65 ± 19.03 67.0 ± 28.46 <0.001a
General health 36.55 ± 21.91 57.85 ± 14.89 0.009a
Vitality 28.0 ± 21.16 50.25 ± 22.75 0.002a
Social functioning 45.0 ± 34.45 70.62 ± 30.58 0.01a
Emotional aspects 34.95 ± 41.38 74.32 ± 38.24 0.003a
Mental health 41.20 ± 32.27 66.40 ± 21.71 0.006a
Pittsburgh Sleep Quality Index
(PSQI)
Subjective sleep quality 1.70 1.20 0.12
Sleep latency 2.10 1.25 0.01a
Sleep duration 1.40 0.85 0.01a
Habitual sleep efﬁciency 1.15 0.45 0.11
Sleep disorders 1.95 1.30 0.002a
Use of sleeping medications 1.65 0.70 0.02a
Daytime dysfunction 1.80 0.90 0.001a
Toronto Alexithymia Scale
(TAS-20)
Ability to identify/describe feelings 36.85 ± 10.64 31.95 ± 7.92 0.01a
Ability to daydream 17.70 ± 5.47 16.60 ± 3.41 0.45
Preference for focusing on external events 12.55 ± 2.91 10.60 ± 2.78 0.03a
CG, control group; PG, patient group; SD, standard deviation.
a p < 0.05.
impact of FM on patients, reducing their QOL and affecting
both their physical and mental health.6,8,18–21
The results of the PSQI demonstrated more  frequent sleep
complaints among patients with FM.  These results are in
accordance with the most recently published studies, which
have highlighted the importance of sleep disorders in the clin-
ical condition and in the QOL of patients with FM.15–18,22,23
Among the aspects studied, the domain “using medica-
tions to sleep” suggests that FM patients rely on medications to
aid sleep and do not reach “habitual sleep efﬁciency” or “sub-
jective sleep quality”. In addition, the domains of “daytime
dysfunction” and “sleep amendment” suggest the persistence
of non-restorative sleep, resulting in a considerable deﬁcit in
the ability to perform daily activities.15–18,22,23 However, even
with signiﬁcant differences in scores between the PG and the
CG on the PSQI, both groups showed low sleep quality (scores
above 5). This ﬁnding can be explained by the stress caused
by both disease and treatment in a tertiary center, to which
the two groups were exposed at the time of the study. Other
studies have also observed such effects when patients with FM
were compared with patients with other chronic and disabling
disorders, such as rheumatoid arthritis and depression.20,21Regarding the presence of alexithymia symptoms mea-
sured using the TAS, the PG presented signiﬁcantly higher
scores than the CG. However, both groups scored very close tothe average, with values adjacent to the “inconclusive inter-
val” of the instrument. This ﬁnding could be a consequence
of the small number of participants, which is an important
limitation of this study.15,23,24 Lane and Sechrest (1998) admin-
istered the TAS-20 to 380 individuals stratiﬁed by age, gender,
socioeconomic status and years of education, and they also
observed that this instrument had a tendency to report worse
results for patients with advanced age, male gender, low
socioeconomic status and fewer years of education.23 There-
fore, one can infer that the present results are also affected by
low socioeconomic status and few years of education, which
were present in both groups, thus narrowing the expected dif-
ference between the PG and the CG.
To conclude, the present study demonstrated that patients
with FM had worse performances in all QOL dimensions of the
SF-36 as well as higher overall scores on the PSQI and the TAS-
20. In addition, patients with FM scored signiﬁcantly higher in
all speciﬁc domains of the PSQI and the TAS-20. Therefore,
broader evaluations using accessible and adequate question-
naires are valuable for characterizing the impact of FM on
patients. Because FM has a multifactorial etiology and vari-
able clinical presentations, more  careful investigation of other
important and frequently underdiagnosed symptoms in this
population, such as sleep complaints and alexithymia, which
occur in addition to pain complaints, is highly encouraged.
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